Tetsufumi Koga

Summary

Affiliation: Daiichi Sankyo Co
Country: Japan

Publications

  1. doi request reprint Antimicrobial resistance in Campylobacter coli and Campylobacter jejuni in cynomolgus monkeys (Macaca fascicularis) and eradication regimens
    Tetsufumi Koga
    Biological Research Laboratories, Daiichi Sankyo Co, Ltd, Tokyo, Japan Electronic address
    J Microbiol Immunol Infect . 2015
  2. pmc Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa
    Tetsufumi Koga
    Biological Research Laboratories IV, Daiichi Sankyo Co, Ltd, Tokyo, Japan
    Antimicrob Agents Chemother 53:1238-41. 2009
  3. pmc Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa
    Tetsufumi Koga
    Biological Research Laboratories IV, Daiichi Sankyo Co, Ltd, 16 13, 1 Chome Kitakasai, Edogawa ku, Tokyo 134 8630, Japan
    Antimicrob Agents Chemother 52:2849-54. 2008
  4. ncbi request reprint [In-vitro activity of panipenem against clinical isolates in 2006]
    Sanae Yoshida
    Post Marketing Study Department, Daiichi Sankyo Co, Ltd, Japan
    Jpn J Antibiot 61:1-17. 2008
  5. doi request reprint In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa
    Takanori Tomozawa
    Biological Research Laboratories IV, Daiichi Sankyo Co Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    J Med Microbiol 59:438-41. 2010
  6. ncbi request reprint [Surveillance of susceptibility of clinical isolates to cefpodoxime between 2000 and 2003]
    Tomomi Abe
    Biological Research Laboratories, Sankyo Co, Ltd
    Jpn J Antibiot 58:259-82. 2005
  7. pmc Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection
    Kiyoshi Sugihara
    Biologics Research Laboratories, Daiichi Sankyo Co Ltd, Edogawa ku, Tokyo 134 8630, Japan
    Antimicrob Agents Chemother 55:5004-9. 2011
  8. pmc In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem
    Tetsufumi Koga
    Biological Research Laboratories, Sankyo Co, Ltd, 2 58 Hiromachi 1 chome, Shinagawa ku, Tokyo 140 8710, Japan
    Antimicrob Agents Chemother 49:3239-50. 2005
  9. pmc In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model
    Kiyoshi Sugihara
    Biological Research Laboratories IV, Daiichi Sankyo Co, Ltd, 16 13, 1 Chome Kitakasai, Edogawa ku, Tokyo 134 8630, Japan
    Antimicrob Agents Chemother 54:5298-302. 2010
  10. ncbi request reprint [Surveillance of susceptibility of clinical isolates to panipenem between 2000 and 2003]
    Tomomi Abe
    Biological Research Laboratories, Sankyo Co, Ltd
    Jpn J Antibiot 58:231-58. 2005

Collaborators

Detail Information

Publications12

  1. doi request reprint Antimicrobial resistance in Campylobacter coli and Campylobacter jejuni in cynomolgus monkeys (Macaca fascicularis) and eradication regimens
    Tetsufumi Koga
    Biological Research Laboratories, Daiichi Sankyo Co, Ltd, Tokyo, Japan Electronic address
    J Microbiol Immunol Infect . 2015
    ..Our animal facility purchased cynomolgus monkeys (Macaca fascicularis) from various Asian countries: China, Cambodia, Indonesia, the Philippines, and Vietnam...
  2. pmc Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa
    Tetsufumi Koga
    Biological Research Laboratories IV, Daiichi Sankyo Co, Ltd, Tokyo, Japan
    Antimicrob Agents Chemother 53:1238-41. 2009
    ..coli and short filamentation with bulges in P. aeruginosa, which correlated with the drug's PBP profiles. The potential of resistance of these bacteria to tomopenem was comparable to that to imipenem...
  3. pmc Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa
    Tetsufumi Koga
    Biological Research Laboratories IV, Daiichi Sankyo Co, Ltd, 16 13, 1 Chome Kitakasai, Edogawa ku, Tokyo 134 8630, Japan
    Antimicrob Agents Chemother 52:2849-54. 2008
    ..aeruginosa should be ascribed to its high affinity for PBP 2a and its activity against the mutants of P. aeruginosa, respectively...
  4. ncbi request reprint [In-vitro activity of panipenem against clinical isolates in 2006]
    Sanae Yoshida
    Post Marketing Study Department, Daiichi Sankyo Co, Ltd, Japan
    Jpn J Antibiot 61:1-17. 2008
    ..In conclusion, 13 years has passed since PAPM was launched in 1993, PAPM still maintains potent antibacterial activity and is considered an effective antimicrobial agent for various types of infectious diseases...
  5. doi request reprint In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa
    Takanori Tomozawa
    Biological Research Laboratories IV, Daiichi Sankyo Co Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo 140 8710, Japan
    J Med Microbiol 59:438-41. 2010
    ..The PAE on MRSA was 1.5 to 3 h, equal to or longer than those of vancomycin. The PAEs of tomopenem not only were found for MRSA, but also were present in the imipenem-resistant P. aeruginosa tested...
  6. ncbi request reprint [Surveillance of susceptibility of clinical isolates to cefpodoxime between 2000 and 2003]
    Tomomi Abe
    Biological Research Laboratories, Sankyo Co, Ltd
    Jpn J Antibiot 58:259-82. 2005
    ..The findings of this surveillance indicate that it is necessary to pay careful attention to the trends of resistant bacteria such as PRSP, BLNAR, and ESBL-producing strains...
  7. pmc Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection
    Kiyoshi Sugihara
    Biologics Research Laboratories, Daiichi Sankyo Co Ltd, Edogawa ku, Tokyo 134 8630, Japan
    Antimicrob Agents Chemother 55:5004-9. 2011
    ..aeruginosa and MRSA strains with MICs of ≤ 8 μg/ml at doses of 750 mg TID and strains with MICs of ≤ 16 μg/ml at doses of 1,500 mg TID...
  8. pmc In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem
    Tetsufumi Koga
    Biological Research Laboratories, Sankyo Co, Ltd, 2 58 Hiromachi 1 chome, Shinagawa ku, Tokyo 140 8710, Japan
    Antimicrob Agents Chemother 49:3239-50. 2005
    ..aeruginosa infections only). These results suggest that CS-023 has potential for the treatment of nosocomial bacterial infections by gram-positive and -negative pathogens, including MRSA and P. aeruginosa...
  9. pmc In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model
    Kiyoshi Sugihara
    Biological Research Laboratories IV, Daiichi Sankyo Co, Ltd, 16 13, 1 Chome Kitakasai, Edogawa ku, Tokyo 134 8630, Japan
    Antimicrob Agents Chemother 54:5298-302. 2010
    ..aeruginosa, and there was no difference between the target values for P. aeruginosa and MRSA required for efficacy in this study...
  10. ncbi request reprint [Surveillance of susceptibility of clinical isolates to panipenem between 2000 and 2003]
    Tomomi Abe
    Biological Research Laboratories, Sankyo Co, Ltd
    Jpn J Antibiot 58:231-58. 2005
    ..aeruginosa also exhibited high resistance. The findings of this surveillance indicate that it is necessary to pay careful attention to the trends of resistant bacteria such as PRSP, BLNAR, and metallo-beta-lactamase producing strains...
  11. doi request reprint Absorption, elimination, and metabolism of CS-1036, a novel α-amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption
    Tomohiro Honda
    Drug Metabolism and Pharmacokinetics Research Laboratories, R and D Division, Daiichi Sankyo Co, Ltd, Tokyo, Japan
    Drug Metab Dispos 41:878-87. 2013
    ..015 mg/kg. In summary, CS-1036 showed optimal pharmacokinetic profiles: low oral absorption and favorable stability in gastrointestinal lumen, resulting in suppression of postprandial hyperglycemia by α-amylase inhibition...
  12. ncbi request reprint Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo
    Tetsufumi Koga
    Biological Research Laboratories, Sankyo Co, Ltd, 2 58 Hiromachi 1 chome, Shinagawa ku, Tokyo 140 8710, Japan
    J Antimicrob Chemother 54:755-60. 2004
    ....